Positive data from the randomized phase IIb AIPAC clinical trial of eftilagimod alpha (efti, LAG-31g, or IMP321) and paclitaxel (Abraxane) in HER2-negative, HR-positive metastatic breast cancer (MBC) was announced by Immutep.
The multicenter, placebo-controlled, double-blind study is evaluating eftilagimod alpha in combination with paclitaxel in a cohort of 277 patients with MBC to try and boost the T-cell immune responses against tumors.
“I am pleased to see this innovative chemo-immunotherapy approach in AIPAC is well tolerated by patients, while showing a numerically (non-significant) higher progression-free survival rate compared to chemotherapy alone,” AIPAC principal investigator Hans Wildiers, of the University Hospitals Leuven in Belgium, said in a press release. “Hormone receptor positive breast tumors represent the majority of metastatic breast cancer patients and…
